Recent blog posts
Non-cystic fibrosis bronchiectasis Indication Strategy Report 2026: DPP1, Trials and Deals
Latest Hotspot
8 min read
Non-cystic fibrosis bronchiectasis Indication Strategy Report 2026: DPP1, Trials and Deals
23 July 2026
2026 Non-cystic fibrosis bronchiectasis strategy: epidemiology, DPP1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Radiation enteritis Indication Strategy Report 2026: TGF-beta, Trials and Deals
Latest Hotspot
8 min read
Radiation enteritis Indication Strategy Report 2026: TGF-beta, Trials and Deals
23 July 2026
2026 Radiation enteritis strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Pouchitis Indication Strategy Report 2026: IL-23, Trials and Deals
Latest Hotspot
8 min read
Pouchitis Indication Strategy Report 2026: IL-23, Trials and Deals
23 July 2026
2026 Pouchitis strategy: epidemiology, IL-23 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Read →
Intestinal failure Indication Strategy Report 2026: GLP-2 receptor, Trials and Deals
Latest Hotspot
8 min read
Intestinal failure Indication Strategy Report 2026: GLP-2 receptor, Trials and Deals
23 July 2026
2026 Intestinal failure strategy: epidemiology, GLP-2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Eosinophilic colitis Indication Strategy Report 2026: IL-5, Trials and Deals
Latest Hotspot
8 min read
Eosinophilic colitis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Eosinophilic colitis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Hirschsprung disease Indication Strategy Report 2026: RET, Trials and Deals
Latest Hotspot
8 min read
Hirschsprung disease Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 Hirschsprung disease strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Chronic intestinal pseudo-obstruction Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
Latest Hotspot
8 min read
Chronic intestinal pseudo-obstruction Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Chronic intestinal pseudo-obstruction strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Bile acid diarrhea Indication Strategy Report 2026: FXR, Trials and Deals
Latest Hotspot
8 min read
Bile acid diarrhea Indication Strategy Report 2026: FXR, Trials and Deals
23 July 2026
2026 Bile acid diarrhea strategy: epidemiology, FXR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Gastroparesis Indication Strategy Report 2026: Ghrelin receptor, Trials and Deals
Latest Hotspot
8 min read
Gastroparesis Indication Strategy Report 2026: Ghrelin receptor, Trials and Deals
23 July 2026
2026 Gastroparesis strategy: epidemiology, Ghrelin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Cyclic vomiting syndrome Indication Strategy Report 2026: NK1 receptor, Trials and Deals
Latest Hotspot
8 min read
Cyclic vomiting syndrome Indication Strategy Report 2026: NK1 receptor, Trials and Deals
23 July 2026
2026 Cyclic vomiting syndrome strategy: epidemiology, NK1 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Functional dyspepsia Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
Latest Hotspot
8 min read
Functional dyspepsia Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Functional dyspepsia strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Porphyria cutanea tarda Indication Strategy Report 2026: UROD, Trials and Deals
Latest Hotspot
8 min read
Porphyria cutanea tarda Indication Strategy Report 2026: UROD, Trials and Deals
23 July 2026
2026 Porphyria cutanea tarda strategy: epidemiology, UROD biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →